The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Xu, Fang ^a,b   Rimm, Alfred A ^a   Fu, Pingfu ^a,c   Krishnamurthi, Smitha S ^a,c   Cooper, Gregory S ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; COLONIC NEOPLASMS; KAPLAN MEIER METHOD; MORTALITY; ODDS RATIO; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; UNITED STATES;

ANTINEOPLASTIC AGENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; NEOPLASM STAGING; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84907192399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107993     Document Type: Article

References (32)

1. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, et al. (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419.
2. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, et al. (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 7: 778-831.
3. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, et al. (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825.
4. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370: 2020-2029.
5. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, et al. (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: 549-557.
6. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, et al. (2005) Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44: 904-912.
7. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B (2010) Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 46: 1049-1055.
8. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, et al. (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. Jama 305: 2335-2342.
9. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, et al. (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29: 3381-3388.
10. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40: Iv-3-18.
11. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31: 732-748.
12. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB (2002) Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20: 3999-4005.
13. Obeidat NA, Pradel FG, Zuckerman IH, DeLisle S, Mullins CD (2009) Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother 7: 343-354.
14. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, et al. (2006) Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107: 2581-2588.
15. Cheung WY, Neville BA, Earle CC (2009) Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for Stage II and III rectal cancer. Dis Colon Rectum 52: 1054-1063; discussion 1064.
16. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, et al. (2006) Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98: 610-619.
17. Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, et al. (2008) Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 112: 789-799.
18. NIH (1990) NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. Jama 264: 1444-1450.
19. Bradley CJ, Given CW, Dahman B, Fitzgerald TL (2008) Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med 168: 521-529.
20. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53: 1258-1267.
21. Parson LS (2001) Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. SUGI 26.
22. Gregg J, Curry RH (1994) Explanatory models for cancer among African-American women at two Atlanta neighborhood health centers: the implications for a cancer screening program. Soc Sci Med 39: 519-526.
23. Powe BD (1995) Fatalism among elderly African Americans. Effects on colorectal cancer screening. Cancer Nurs 18: 385-392.
24. Shankar S, Selvin E, Alberg AJ (2002) Perceptions of cancer in an African-American community: a focus group report. Ethn Dis 12: 276-283.
25. Delea TE, Vera-Llonch M, Edelsberg JS, McGarry L, Anton S, et al. (2002) The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 5: 35-43.
26. Ahmed S, Ahmad I, Zhu T, Arnold FP, Faiz Anan G, et al. (2010) Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum 53: 1432-1438.
27. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, et al. (1998) Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 34: 1693-1700.
28. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, et al. (2006) Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65: 1353-1360.
29. Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, et al. (2013) Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 30: 419.
30. Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T (1978) Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088-2098.
31. Schabel F (1977) Experimental basis of adjuvant chemotherapy. In SE Salmon and SE JOnes (eds): Adjuvant therapy of cancer: 3-14.
32. Grann VR, Muggia FM (2006) Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective. J Natl Cancer Inst 98: 570-571.